Related Experiment Videos
[Topical carbonic anhydrase inhibitors in the treatment of glaucoma]
A Bayer1, F Ferrari, T H Maren
1Department of Ophthalmology, Mount Sinai Medical Center, New York City, USA.
Journal Francais D'Ophtalmologie
|January 1, 1996
Abstract:
Systemically administered carbonic anhydrase inhibitors have been in clinical use since the 1950's. Their use and side effects have been reviewed extensively. Our review summarizes the development of topically administered carbonic anhydrase inhibitors in patients with glaucoma. Moreover, it documents clinical trials leading to the present choice of dorzolamide (MK-507), which is now being reviewed for worldwide approval for marketing by 1995.